HIV-drug

Mitochondria-associated toxicities, such as pancreatitis, are frequently demonstrated in HlV/HCV-coinfected individuals, and may significantly influence treatment options (de Mendoza and Soriano 2005). Yet, no cell culture or animal models have been developed to predict nucleoside-induced pancreatitis. Nevertheless, an association of HCV replication and mitochondrial DNA depletion in primary human lymphocytes obtained from HIV/HCV-coinfected individuals under concomitant administration of HCV and HIV medications was demonstrated by de Mendoza and coworkers (de Mendoza et al. 2007). They claimed that the use of HCV medication together with certain antiretroviral agents seemed to enhance mitochondrial damage due to a synergistic deleterious interaction between the anti-HCV and anti-HIV drugs. In contrast, an improvement in mitochondrial content with effective... 

Deval J, D Abramo CM, GOtte M (2006) Selective excision of non-obUgate chain-terminators by the hepatitis C virus NS5B polymerase. In 16th international HIV Drug Resistance workshop, Sitges, Spain, June 13-17, 2006. Antivir Ther 11 Suppl 1 S3 (abstract no 1)... 

Storch CH, Theile D, Lindenmaier H, Haefeh WE, Weiss J (2007) Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein, Biochem Pharmacol 73 1573-1581... 

The number of studies for other countries is limited. Krentz et al. (2003) analyzed the provider costs of providing medical care to patients with HIV/AIDS in Southern Alberta Canada) between April 1995 and April 2001. The authors collected all patient-specific provider costs including the cost of drugs (HIV and non-HIV drugs), outpatient care (including physician costs and laboratory testing), and... 

This HIV drug is a CYP3A4 inducer efavirenz decreases... 

Nervirapine is an HIV drug that is a CYP3A4 inducer in a small sample, nevirapine caused a 50% reduction in methadone blood levels, resulting in complaints of methadone withdrawal symptoms in patients receiving methadone maintenance may need to increase methadone dose in patients who have nevirapine added to their drug regimen. 

Princen K, Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev 2005 16(6) 659-677. 

There are a few key enzymes for the proliferation of human immunodeficiency virus (HIV). Reverse transcriptase is one of them since HIV is a member of the DNA viruses. Efavirenz (1) is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) and was discovered at Merck Research Laboratories [1] for treatment of HIV infections. Efavirenz was originally licensed to DuPont Merck Pharmaceuticals which was later acquired by Bristol-Myers Squibb.11 The typical adult dose is 600 mg once a day and 1 is one of three key ingredients of the once-a-day oral HIV drug, Atripla (Figure 1.1). 

The most effective means to accomplish durable suppression of HIV replication is the simultaneous initiation of combinations of effective anti-HIV drugs with which the patient has not been previously treated and that are not cross resistant with antiretroviral agents with which the patient has been treated previously. 

The optical purity of compound (304) is due to the high facial preference of the attack of the olefin on nitronate (303) from the distal side with respect to the substituents at the C-4 and C-6 atoms. Modifications of nucleotides provide a promising approach to the synthesis of new anti-HIV drugs. 

See also Gravimetric techniqugges Acoustic waves, sensors using, 22 269-270 Acoustooptic (AO) modulators, 14 676 Acousto-ultrasonics, in nondestructive evaluation, 17 425-426 Acquired Immunodeficiency Syndrome (AIDS), 3 135 25 500. See also Anti-HIV drug candidates HIV entries Nevirapine entries sulfonamide exposure in, 23 506 Acquisitions, 15 639 Acrawax C, dental wax, 8 296 9-Acridinecarbonylimidazole, as... 

Such dideoxynucleosides as CNT (306) and the potent anti-HIV drug ddC (307) have been obtained (280), respectively, from the butenolide 248 and from its saturated analogue. Thus, conjugate addition of cyanide to 248, followed by reduction of the lactone group, acetylation of HO-1, and coupling with silylated thymine, afforded, after deprotection, compound 306. 

Wainberg, M.A. and Friedland, G., Public health implications of antiretroviral therapy and HIV drug resistance, JAMA, 279,1977-1983,1998. 

---